Garcia-Gonzalez Montserrat, Iglesias-Iglesias MariLuz, Drake Rodriguez-Casanova Pilar, Gros-Otero Juan, Teus Miguel A
J Refract Surg. 2018 Jan 1;34(1):23-28. doi: 10.3928/1081597X-20171116-01.
To compare the visual and refractive results of femtosecond laser-assisted LASIK (FS-LASIK) with and without the adjuvant use of mitomycin C (MMC) to correct hyperopia.
A total of 152 consecutive hyperopic eyes were included in this retrospective, observational cohort study, comparing 76 eyes treated with FS-LASIK + MMC with 76 age- and refraction-matched eyes treated with FS-LASIK without MMC. Visual and refractive results were evaluated 1 day, 1 week, and 1, 3, 6, and 15 months postoperatively.
Preoperative mean spherical equivalent was +3.27 diopters (D) versus +3.50 D in the MMC and no MMC groups, respectively (P > .05). Three months postoperatively, uncorrected distance visual acuity was significantly better in the MMC group (0.93 ± 0.2) than in the no MMC group (0.87 ± 0.2) (P = .01). The residual spherical equivalent was significantly lower in the MMC group (+0.18 ± 0.40 D) than in the no MMC group (+0.42 ± 0.50 D) (P = .01). Fifteen months postoperatively, including re-treated eyes, no significant differences were found in uncorrected distance visual acuity, corrected distance visual acuity, and residual refraction. Slightly better outcomes were found in the MMC group in terms of efficacy, safety, and predictability; however, these small differences were not statistically significant. The incidence of re-treatments during the 15-month follow-up was significantly lower in the MMC group than in the no MMC group (6.6% vs 10.5%, respectively) (P = .01).
FS-LASIK with or without the intraoperative use of MMC is safe and effective to correct hyperopia. However, slightly better refractive outcomes and a lower incidence of re-treatments were observed when intraoperative MMC was used, at least in a 15-month follow-up. [J Refract Surg. 2018;34(1):23-28.].
比较飞秒激光制瓣准分子原位角膜磨镶术（FS-LASIK）联合与不联合使用丝裂霉素C（MMC）矫正远视的视觉和屈光效果。
本回顾性观察队列研究共纳入152只连续的远视眼，将76只接受FS-LASIK联合MMC治疗的眼与76只年龄和屈光度匹配的未接受MMC治疗的FS-LASIK眼进行比较。术后1天、1周、1、3、6和15个月评估视觉和屈光效果。
术前平均球镜等效度在MMC组和未使用MMC组分别为+3.27屈光度（D）和+3.50 D（P >.05）。术后3个月，MMC组的未矫正远视力（0.93±0.2）明显优于未使用MMC组（0.87±0.2）（P =.01）。MMC组的残余球镜等效度（+0.18±0.40 D）明显低于未使用MMC组（+0.42±0.50 D）（P =.01）。术后15个月，包括再次治疗的眼，在未矫正远视力、矫正远视力和残余屈光度方面未发现显著差异。在疗效、安全性和可预测性方面，MMC组的结果略好；然而，这些微小差异无统计学意义。MMC组在15个月随访期间的再次治疗发生率明显低于未使用MMC组（分别为6.6%和10.5%）（P =.01）。
FS-LASIK联合或不联合术中使用MMC矫正远视都是安全有效的。然而，至少在15个月的随访中，术中使用MMC时观察到屈光效果略好且再次治疗发生率较低。[《屈光手术杂志》。2018；34(1):23 - 28。]
